Newsfeeds - Spark Newswire

2 minute read

Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations

Today, 5:48 AM

Illumina, Inc. (NASDAQ:ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the

ILMN

1 minute read

Morgan Stanley Downgrades Merck & Co to Equal-Weight, Lowers Price Target to $85

By Benzinga Newsdesk

Today, 5:48 AM

Morgan Stanley analyst Matthew Harrison downgrades Merck & Co (NYSE:MRK) from Overweight to Equal-Weight and lowers the price target from $90 to $85.

MRK

1 minute read

Pfizer Commences Dosing In Pivotal Oral COVID-19 Drug Trial

By Vandana Singh

Today, 5:48 AM

Pfizer Inc (NYSE: PFE) has started dosing in Phase 2/3 trial of its oral antiviral therapy for COVID-19 in non-hospitalized, symptomatic adult patients. The trial would enroll 1,140 participants who will receive PF07321332/ritonavir combo or placebo every 12 hours for five days.

MRK

1 minute read

Pete Najarian Sees Unusual Options Activity In Merck And FXI

By Craig Jones

Today, 5:48 AM

Pete Najarian spoke on CNBC's "Fast Money Halftime Report" about unusually high options activity in Merck & Co., Inc. (NYSE: MRK) and iShares China Large-Cap ETF (NYSE:

FXI

1 minute read

Merck Shares Rebound From Session Low, Spike To Afternoon High; Hearing Jon Najarian Mentioned Unusual Option Activity On CNBC’s ‘Fast Money: Halftime Report’

By Benzinga Newsdesk

Today, 5:48 AM

-TradeXchange

MRK

1 minute read

Pre-Market Outlook

Benzinga Pro’s Top 5 Stocks To Watch For Monday, Aug. 30, 2021: MRNA, AFRM, MRK, BBIG, GSAT

By Benzinga Newsdesk

Today, 5:48 AM

Today's 5 Stock Ideas: Moderna (MRNA) - Shares were down 2% Monday following weekend news Japan's Health Ministry said it will investigate the deaths of two men who received a COVID-19 vaccine shot.

AAPL

2 minute read

The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck’s Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week

By Shanthi Rexaline

Today, 5:48 AM

Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc.

ADGI

5 minute read

The Daily Biotech Pulse: Early Approval For Ascendis’ Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO

By Shanthi Rexaline

Today, 5:48 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25)

ABBV

3 minute read

Global
News

Merck’s KEYTRUDA Receives Two New Approvals in Japan

By Benzinga Newsdesk

Today, 5:48 AM

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has received two new approvals from the Japan Pharmaceuticals and Medical Devices Agency

MRK

4 minute read

The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer’s Drug

By Shanthi Rexaline

Today, 5:48 AM

ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24)

AGEN